Buy and Bill Use Decreases as 2020 Approaches

$0.00

Buy and Bill Use Decreases as 2020 Approaches. Understanding provider-administered drug reimbursement is an ongoing challenge for industry stakeholders. Providers, patients and payers face issues that need to be addressed by companies launching or selling products into this market.

Access Market Intelligence’s ongoing research and client advisory services has monitored the trend of Buy and Bill use and works with clients to minimize the impact it has on specific products in the market. The one certainty is that the percentage of Buy and Bill disruption is not uniform in the marketplace and it depends on a company’s specific product(s).